Clinical Development Clinical Research Disease Pharmaceutical Companies 
Drug Discovery World
DECEMBER 22, 2022
Shelley McLendon , SVP of Vaccine and Infectious Diseases Program Management at ICON, attended the World Vaccine Congress Europe from 16-19 October 2022 in Barcelona, Spain. Disease surveillance and reporting . Disease surveillance is the collection and monitoring of data on disease within a population.
Drug Discovery World
MARCH 5, 2024
We now commonly refer to epilepsy as ‘epilepsies’, with the recognition that it isn’t a singular disease. Here, we are building on learnings from other epilepsies where tissue is available as well as genetics to help understand universal disease mechanisms across epilepsies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
SEPTEMBER 5, 2024
I am a pharmacist by training and continued with a PhD in Clinical Pharmacology. However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company.
Vial
APRIL 10, 2024
The increasing costs associated with in-house drug development have prompted biotech and pharmaceutical companies to increasingly outsource to contract research organization s (CROs) for assistance. The company reported a revenue of $11,116 million for the first nine months of 2023, marking a 4.2%
The Pharma Data
JANUARY 4, 2021
for expanding activities in the US with its initial focus on facilitating clinical development. Outline of the new company (1) Company name: Meiji Pharma USA Inc. (2) Location: 500 Frank W. (6) Established: 4 July, 2020 (7) Shareholding structure: Wholly-owned by Meiji Seika Pharma Co.,
The Pharma Data
JANUARY 6, 2021
“Further, PDE4-inhibition is a well-documented pharmacological target for a number of other inflammatory indications, and we look forward to advancing our clinical research to realize the full potential of orismilast for the benefit of the millions of patients living with inflammatory conditions globally,” adds Professor Sommer.
The Pharma Data
JANUARY 24, 2021
Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. Research and development efforts will be led by Dr. Paul Van Slyke.
Expert insights. Personalized for you.
130 
Let's personalize your content